KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts

Annals of Hematology

Volumn 93, Issue 9, 2014, Pages 1579-1586

  Michaelis, Sebastian U ^a   Mezger, Markus ^a   Bornhäuser, Martin ^b   Trenschel, Rudolf ^c   Stuhler, Gernot ^d   Federmann, Birgit ^a   Oevermann, Lena ^a   Kanz, Lothar ^a   Handgretinger, Rupert ^a   Bethge, Wolfgang A ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Haploidentical hematopoietic cell transplantation; KIR haplotype; KIR ligand model

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CD3 CD19 DEPLETED GRAFT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DONOR; FEMALE; GENOTYPE; HAPLOTYPE; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; STEM CELL; VIRUS REACTIVATION;

ADULT; ANTIGENS, CD19; ANTIGENS, CD3; BLOOD GROUP INCOMPATIBILITY; CELL SEPARATION; FEMALE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RECEPTORS, KIR; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84905571776     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2084-2     Document Type: Article

References (37)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44-49. doi:10.1126/science.1198687
2. Parmar S, Fernandez-Vina M, de Lima M (2011) Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia. Curr Opin Hematol 18(2):98-104. doi:10.1097/MOH.0b013e328343b858
3. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239-252. doi:10.1038/nri3174
4. Hsu KC, Chida S, Geraghty DE, Dupont B (2002) The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190:40-52 (Pubitemid 36071925)
5. Passweg JR, Huard B, Tiercy JM, Roosnek E (2007) HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol 28(10):437-441. doi:10.1016/j.it.2007.07.008 (Pubitemid 47444551)
6. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7(6):753-763 (Pubitemid 28064889)
7. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116(14):2411-2419. doi:10.1182/blood-2010-05-283051
8. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ (2009) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113(3):726-732. doi:10.1182/blood-2008-07-171926
9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097-2100. doi:10.1126/science. 1068440 (Pubitemid 34229476)
10. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM (2010) Genotypes of NK cell KIR receptors, their ligands, and Fc gamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23):9554-9561. doi:10.1158/0008-5472. CAN-10-2211
11. Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge WA (2012) Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. doi:10.3324/haematol.2011.059378
12. Federmann B, Hagele M, Pfeiffer M, Wirths S, Schumm M, Faul C, Vogel W, Handgretinger R, Kanz L, Bethge WA (2011) Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 25(1):121-129. doi:10.1038/leu.2010.235
13. Alves LG, Rajalingam R, Canavez F (2009) A novel real-time PCR method for KIR genotyping. Tissue Antigens 73(2):188-191. doi:10.1111/j.1399-0039.2008. 01184.x
14. Vilches C, Castano J, Gomez-Lozano N, Estefania E (2007) Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 70(5):415-422. doi:10.1111/j.1399-0039.2007.00923.x (Pubitemid 47537402)
15. Schonberg K, Sribar M, Enczmann J, Fischer JC, Uhrberg M (2011) Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 117(1):98-107. doi:10.1182/blood-2010-03-273656
16. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110(1):433-440. doi:10.1182/blood-2006- 07-038687 (Pubitemid 47026866)
17. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381-387. doi:10.1038/sj.bmt.1705727 (Pubitemid 47202424)
18. Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388-1395. doi:10.1038/bmt.2009.359
19. Bleakley M, Riddell SR (2004) Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4(5):371-380. doi:10.1038/nrc1365 (Pubitemid 38579483)
20. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, Nagler A, Slavin S (2004) The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63(3):204-211. doi:10.1111/j.0001-2815.2004.00182.x
21. Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP (2007) Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 21(4):848-851. doi:10.1038/sj.leu.2404566
22. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi S, Lupo Stanghellini MT, Mazzi B, Perna SK, Bondanza A, Middleton D, Palini A, Bernardi M, Bacchetta R, Peccatori J, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K (2008) Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 112(8):3488-3499. doi:10.1182/blood-2007-07-103325
23. Kroger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stubig T, Hilde-brandt Y, Atanackovic D, Alchalby H, Ayuk F, Zander AR, Bacher U, Eiermann T (2011) Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 25(10):1657-1661. doi:10.1038/leu.2011.138
24. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ (2010) Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 16(4):533-542. doi:10.1016/j.bbmt.2009.11.022
25. Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf E, Hsu KC (2010) Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 115(15):3162-3165. doi:10.1182/blood-2009-08-236943
26. Kim HJ, Choi Y, Min WS, Kim TG, Cho BS, Kim SY, Eom KS, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim CC (2007) The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 84(9):1082-1091. doi:10.1097/01.tp.0000285918.72930.35 (Pubitemid 350125348)
27. Verheyden S, Schots R, Duquet W, Demanet C (2005) A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19(8):1446-1451. doi:10.1038/sj.leu.2403839 (Pubitemid 41136340)
28. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P (2007) Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68(5):309-323. doi:10.1016/j.humimm.2007.01. 019 (Pubitemid 46616984)
29. Sun JY, Gaidulis L, Dagis A, Palmer J, Rodriguez R, Miller MM, Forman SJ, Senitzer D (2005) Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 36(6):525-530. doi:10.1038/sj.bmt.1705089 (Pubitemid 43118147)
30. Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A (2006) Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 82(8):1024-1030. doi:10.1097/01.tp.0000235859.24513.43 (Pubitemid 44632116)
31. Giebel S, Nowak I, Wojnar J, Markiewicz M, Dziaczkowska J, Wylezol I, Krawczyk-Kulis M, Bloch R, Kusnierczyk P, Holowiecki J (2006) Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc 38(1):287-291. doi:10.1016/j.transproceed.2005.11.091
32. Leung W (2011) Use of NK cell activity in cure by transplant. Br J Haematol 155(1):14-29. doi:10.1111/j.1365-2141.2011.08823.x
33. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P (2006) Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107(3):1230-1232. doi:10.1182/blood-2005-03-1039 (Pubitemid 43156330)
34. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100(10):3825-3827. doi:10.1182/blood-2002-04-1197 (Pubitemid 35303959)
35. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367(9):805-816. doi:10.1056/NEJMoa1200503
36. Elishmereni M, Bachelet I, Levi-Schaffer F (2008) DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders. Curr Opin Investig Drugs 9(5):491-496 (Pubitemid 351677903)
37. Koch J, Steinle A, Watzl C, Mandelboim O (2013) Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 34(4):182-191. doi:10.1016/j.it.2013.01.003